MedTrace Logo

Placebo vs. Linoleic Acid Controlled Assessment of Treatment Efficacy in MS

NCT00638196 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2015-08-11

No results posted yet for this study

Summary

Several investigations have suggested that polyunsaturated fatty acids may promote therapeutic effects in MS. This pilot study will determine whether omega-6 polyunsaturated fatty acids (PUFAs),in the form of linoleic acid,can reduce disease activity and prevent disability progression in patients with relapsing MS.This study will seek to measure disease activity as seen on MRI scans in addition to measuring relapse rates.

Conditions

Interventions

DRUG

Linoleic Acid/Oleic Acid

Dietary Supplement: Linoleic acid emulsion 30g bid/Oleic acid emulsion 30g bid

Sponsors & Collaborators

  • University of Rochester

    lead OTHER

Principal Investigators

  • Andrew D Goodman, MD · University of Rochester

Study Design

Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2012-09-30
Completion
2012-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00638196 on ClinicalTrials.gov